Cory Renauer
TMFang4apples
Cory Renauer is a contributing Healthcare Analyst at The Motley Fool, covering publicly traded companies across pharmaceuticals, biotechnology, and medical devices. Prior to The Motley Fool, Cory was an educator in Thailand and a laboratory technician for the American Red Cross. He holds a B.S. in Biology from Oakland University. Fun fact: Cory has a collection of novelty socks featuring famous stock market symbols and iconic investor quotes.
Recent Articles by Cory Renauer

Apr 22, 2025
by Cory Renauer
Is Beaten-Down Coupang Stock a Buy on the Dip?

Mar 15, 2025
by Cory Renauer
Down 93%, Is It Finally Time to Buy Moderna?

Mar 11, 2025
by Cory Renauer
Down 62%. Should You Buy TransMedics Stock on the Dip?

Mar 5, 2025
by Cory Renauer
Down 39%. Is Novo Nordisk Stock a Buy on the Dip?

Feb 10, 2025
by Cory Renauer
Better High-Yield Dividend Stock: Pfizer vs. Merck
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.